Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System Including Lightning™ Intelligent Aspiration to Japan
22 September 2022 - 03:00PM
Business Wire
- Companies aim to introduce Penumbra’s most advanced peripheral
mechanical thrombectomy technology to Japan upon regulatory
approval
- Lightning technology is designed for single session blood clot
removal in peripheral arterial and venous systems, including for
diseases such as acute limb ischemia, vein thrombosis and pulmonary
embolism
- First and only computer-aided mechanical aspiration technology
that can differentiate between clot and blood, which is designed to
minimize blood loss
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused
on innovative therapies, and Asahi Intecc Co., a leading Japanese
medical device manufacturer, announced that they will collaborate
to introduce Penumbra’s Indigo™ Aspiration System into the Japanese
market upon regulatory approval.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220922005290/en/
Penumbra, Inc. and Asahi Intecc Co. will
collaborate to introduce Penumbra’s Indigo™ Aspiration System into
the Japanese market upon regulatory approval. Penumbra’s Indigo
Aspiration System can be used to remove emboli and thrombi from
vessels of the peripheral arterial and venous systems, and for
treatment of pulmonary embolism. A minimally-invasive device,
Indigo enables the restoration of blood flow in such cases as acute
limb ischemia and venous thrombus. Penumbra’s newest generation
offering combines hypotube-based Indigo Aspiration Catheters with
Lightning Intelligent Aspiration, a unique computer-aided clot
detection technology that can differentiate between clot and blood,
designed to reduce blood loss and the need for clot-dissolving
drugs, which may lower the risk of bleeding complications.
(Graphic: Business Wire)
“By bringing together our newest innovations with Asahi’s
leadership and expertise in the Japanese medical device market, we
can provide physicians in Japan with technology that has been
proven highly effective, helping patients return home quickly and
in good health,” said Adam Elsesser, president and chief executive
officer of Penumbra. “This furthers our commitment to advance novel
technologies to address unmet needs and improve patient care
worldwide.”
Penumbra’s Indigo Aspiration System can be used to remove emboli
and thrombi from vessels of the peripheral arterial and venous
systems, and for treatment of pulmonary embolism. A
minimally-invasive device, Indigo enables the restoration of blood
flow in such cases as acute limb ischemia and venous thrombus.
Penumbra’s newest generation offering combines hypotube-based
Indigo Aspiration Catheters with Lightning Intelligent Aspiration,
a unique computer-aided clot detection technology that can
differentiate between clot and blood, designed to reduce blood loss
and the need for clot-dissolving drugs, which may lower the risk of
bleeding complications.
“Our companies share a similar mission to help expand the
available treatment options for serious conditions that impact an
increasing number of people in Japan,” said Masahiko Miyata,
president and chief executive officer of Asahi Intecc. “We believe
that, together, we are able to provide physicians with the latest
innovations that best meet their patients’ needs and help advance
patient care.”
Penumbra’s neurovascular thrombectomy and neurovascular and
peripheral embolization devices will continue to be distributed by
its long-time trusted partner, Medico’s Hirata. This includes the
latest RED™ reperfusion catheters, which are designed with
optimized trackability and aspiration efficiency to help navigate
the complex anatomy of the brain and deliver efficient aspiration
for the removal of blood clots in a broad range of stroke
patients.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a
global healthcare company focused on innovative therapies. Penumbra
designs, develops, manufactures and markets novel products and has
a broad portfolio that addresses challenging medical conditions in
markets with significant unmet need. Penumbra supports healthcare
providers, hospitals and clinics in more than 100 countries. For
more information, visit www.penumbrainc.com and connect on Twitter
and LinkedIn.
Important Safety Information
Additional information about Penumbra’s products can be located
on Penumbra’s website at
http://www.penumbrainc.com/healthcare-professionals. Prior to use,
please refer to Instructions for Use for complete product
indications, contraindications, warnings, precautions, potential
adverse events and detailed instructions for use. Risk information
can be found here.
Forward-Looking Statements
Except for historical information, certain statements in this
press release are forward-looking in nature and are subject to
risks, uncertainties and assumptions about us. Our business and
operations are subject to a variety of risks and uncertainties and,
consequently, actual results may differ materially from those
projected by any forward-looking statements. Factors that could
cause actual results to differ from those projected include, but
are not limited to: the impact of the COVID-19 pandemic on our
business, results of operations and financial condition; failure to
sustain or grow profitability or generate positive cash flows;
failure to effectively introduce and market new products; delays in
product introductions; significant competition; inability to
further penetrate our current customer base, expand our user base
and increase the frequency of use of our products by our customers;
inability to achieve or maintain satisfactory pricing and margins;
manufacturing difficulties; permanent write-downs or write-offs of
our inventory; product defects or failures; unfavorable outcomes in
clinical trials; inability to maintain our culture as we grow;
fluctuations in foreign currency exchange rates; potential adverse
regulatory actions; and the potential impact of any acquisitions,
mergers, dispositions, joint ventures or investments we may make.
These risks and uncertainties, as well as others, are discussed in
greater detail in our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K for the
year ended December 31, 2021, filed with the SEC on February 22,
2022. There may be additional risks of which we are not presently
aware or that we currently believe are immaterial which could have
an adverse impact on our business. Any forward-looking statements
are based on our current expectations, estimates and assumptions
regarding future events and are applicable only as of the dates of
such statements. We make no commitment to revise or update any
forward-looking statements in order to reflect events or
circumstances that may change.
Source: Penumbra, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220922005290/en/
Jennifer Heth Penumbra, Inc jheth@penumbrainc.com
510-995-9791
Joni Ramirez Merryman Communications
joni@merrymancommunications.com 323.532.0746
Penumbra (NYSE:PEN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Penumbra (NYSE:PEN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024